Sedative / Hypnotics

Point-of-Sale (POS) edits are safety limitations that are automatically verified through computer programming at the time that a prescription claim is submitted at the pharmacy. These edits can be applied to *any* medication, whether or not it is listed in the Preferred Drug List / Non-Preferred Drug List (PDL/NPDL). The first section of this document is organized to follow the order of the therapeutic classes in the PDL/NPDL and explains the POS edits for those medications.

POS Abbreviations

AL – Age Limit	**DD** – Drug-Drug Interaction	**MD** – Maximum Dose Limit	**TD** - Therapeutic Duplication
BH – Behavioral Health Clinical Authorization for Children Younger than 7 Years of Age	**DS** Maximum Days' Supply Allowed	**PR** – Enrollment in a Physician-Supervised Program Required	**UN** – Drug Use Not Warranted
BY – Diagnosis Codes Bypass Some Requirements	**DT** – Duration of Therapy Limit	**PU** – Prior Use of Other Medication is Required	**X** – Prescriber Must Have 'X' DEA Number
CL – Additional Clinical Information is Required	**DX** – Diagnosis Code Requirement	**QL** – Quantity Limit	**YQ** – Yearly Quantity Limit
CU – Concurrent Use with Other Medication is Restricted	**ER** – Early Refill	**RX** – Specific Prescription Requirement	

Pharmacy Prior Authorization Phone Numbers for MCOs and FFS
Aetna Better Health of Louisiana **1-855-242-0802**
AmeriHealth Caritas Louisiana **1-800-684-5502**
Fee-for-Service (FFS) Louisiana Legacy Medicaid **1-866-730-4357**
Healthy Blue **1-844-521-6942**
Louisiana Healthcare Connections **1-888-929-3790**
UnitedHealthcare **1-800-310-6826**

Sedative / Hypnotics

POS Edits

BH – Additional behavioral-health related clinical information (trial of behavioral therapy, etc.) is required for doxepin when requested for recipients who are younger than 7 years of age.

CL – Additional clinical information (prescriber specialty, severity of diagnosis, etc.) is required for tasimelteon.

MD – Sedative/hypnotics have a maximum daily dose as listed in the chart to the right.

Maximum Daily Dose for Selected Sedative/Hypnotics

Generic Name (Brand Example)	Maximum Dose Per Day
Doxepin (Silenor®)	6 mg/day
Estazolam (ProSom®)	2 mg/day
Eszopiclone (Lunesta®)	3 mg/day
Flurazepam (Dalmane®)	30 mg/day
Lemborexant (Dayvigo®)	10 mg/day
Quazepam (Doral®)	15 mg/day
Ramelteon (Rozerem®)	8 mg/day
Suvorexant (BELSOMRA®)	20mg/day
Tasimelteon (Hetlioz®)	20mg/day
Temazepam (Restoril®)	30 mg/day
Triazolam (Halcion®)	0.5 mg/day
Zaleplon (Sonata®)	20 mg/day
Zolpidem IR tablet (Ambien®)	10 mg/day
Zolpidem SL tablet (Edluar®)	10 mg/day
Zolpidem Oral Spray (ZolpiMist®)	10 mg (2sprays)/day
Zolpidem ER Tablet (Ambien CR®)	12.5 mg/day
Zolpidem SL Tablet (Intermezzo®)	1.75mg/day (female)
Zolpidem SL Tablet (Intermezzo®)	3.5 mg/day (male)

QL

- Pharmacy claims for all sedative/hypnotic agents (except ~~lemborexant,~~ tasimelteon capsule and zolpidem oral spray) are limited to:
  - A quantity of 7 per rolling 30 days for recipients who have no sedative/hypnotic pharmacy claims in the previous 60-day period
  - A quantity of 15 per rolling 30 days for recipients who have any sedative/hypnotic pharmacy claim in the previous 60-day period
- ~~Lemborexant (Dayvigo™) is limited to a maximum quantity of 7 tablets per rolling 30 days.~~
- Tasimelteon (Hetlioz LQ™) is limited to a maximum quantity of 150 ml~~s~~ per 30 days.

TD – These agents are monitored at the pharmacy POS for duplication of therapy with other sedative/hypnotic agents.

Revision / Date	Implementation Date
Created POS Document	February 2020
Added Dayvigo™ POS edits (including quantity limit) / July 2020	October 2020
Added quantity limits to all other sedative/hypnotics (except Hetlioz® and ZolpiMist®) / September 2020	January 2021
Modified to apply new age requirement for behavioral health clinical authorization / November 2020	January 2021
Added Hetlioz LQ™ / May 2021	October 2021
~~Changed~~Modified quantity limit for Dayvigo®~~®~~~~™~~ / June 2021	